Repositioning Candidate Details
| Candidate ID: | R0175 |
| Source ID: | DB00623 |
| Source Type: | approved |
| Compound Type: | small molecule |
| Compound Name: | Fluphenazine |
| Synonyms: | |
| Molecular Formula: | C22H26F3N3OS |
| SMILES: | OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1 |
| Structure: |
|
| DrugBank Description: | A phenothiazine used in the treatment of psychoses. Its properties and uses are generally similar to those of chlorpromazine. |
| CAS Number: | 69-23-8 |
| Molecular Weight: | 437.522 |
| DrugBank Indication: | For management of manifestations of psychotic disorders. |
| DrugBank Pharmacology: | Fluphenazine is a trifluoro-methyl phenothiazine derivative intended for the management of schizophrenia and other psychotic disorders. Fluphenazine has not been shown effective in the management of behaviorial complications in patients with mental retardation. |
| DrugBank MoA: | Fluphenazine blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis. |
| Targets: | Dopamine D2 receptor; Dopamine D1 receptor; Calmodulin; Androgen receptor; 5-hydroxytryptamine receptor 2A; 5-hydroxytryptamine receptor 2C |
| Inclusion Criteria: |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I02 | 1184 | nephrotic syndrome | "A nephrosis characterized by marked increase in glomerular protein permeability resulting in marked elevation of urine protein levels, hypoalbuminemia, hyperlipidemia, and hypercoagulability." [url:https\://en.wikipedia.org/wiki/Nephrotic_syndrome, url:https\://www.niddk.nih.gov/health-information/kidney-disease/nephrotic-syndrome-adults] | Details |